Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H17FN4O3 |
Molecular Weight | 308.3082 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(C=N1)C2=C(F)C=C(C=C2)N3C[C@H](CO)OC3=O
InChI
InChIKey=QLUWQAFDTNAYPN-LLVKDONJSA-N
InChI=1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3/t11-/m1/s1
Molecular Formula | C14H17FN4O3 |
Molecular Weight | 308.3082 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL612318 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20855730 |
|||
Target ID: CHEMBL612624 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20855730 |
|||
Target ID: CHEMBL355 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20855730 |
|||
Target ID: CHEMBL614429 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20855730 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:42:25 GMT 2023
by
admin
on
Sat Dec 16 09:42:25 GMT 2023
|
Record UNII |
43EP6XV33E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
590317
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1219707-39-7
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY | |||
|
43EP6XV33E
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY | |||
|
C166717
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY | |||
|
DB13077
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY | |||
|
300000034072
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY | |||
|
10479
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY | |||
|
44205191
Created by
admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
MBC99
|
||
|
TARGET ORGANISM->INHIBITOR |
Resistant rate of MDR-TB = 0.8%
MIC90
|
||
|
TARGET ORGANISM->INHIBITOR |
MIC
|
||
|
TARGET ORGANISM->INHIBITOR |
Resistant rate of MDR-TB = 4.2%
MIC90
|
||
|
TARGET ORGANISM->INHIBITOR |
A broad spectrum antibiotic.In
phase I clinical trials, found to have better safety (milder side effects) than LZD due to its more rapid
clearance,88 although final results from a phase IIa EBA
study may suggest lower efficacy than both LZD and sutezolid.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|